Oscotec's Q3 Cumulative Revenue Rises Threefold YoY to 62.8 Billion Won

Returned to Operating Profit of KRW 22 Billion
Lazertinib Royalties Reach KRW 9.5 Billion

Oscotec disclosed on November 13 that its consolidated results for the first three quarters of the year included cumulative revenue of 62.866 billion won and operating profit of 21.996 billion won.

Cumulative revenue increased approximately threefold from 20.898 billion won in the same period last year, while the company turned to operating profit. The improvement was driven by the upfront payment for the licensing of sevudiplenib recognized in the first half, as well as milestone and royalty income related to lazertinib.

Oscotec corporate logo image. Oscotec

Cumulative milestone and royalty income from lazertinib for the first three quarters of this year totaled 24.598 billion won. Royalty income accounted for 9.526 billion won, exceeding the full-year total of 7.531 billion won last year by 26.5%. Annual royalty income rose steadily from 1.073 billion won in 2022 to 1.287 billion won in 2023, 2.636 billion won in 2024, and 7.531 billion won in 2025.

The 35.993 billion won upfront payment for sevudiplenib, which was licensed to U.S. rare disease-focused pharmaceutical company Agios Pharmaceuticals in June, was reflected in the second-quarter results. Agios is developing sevudiplenib as a treatment for immune thrombocytopenia (ITP) and is continuing development, with the goal of entering Phase 3 trials in the first half of 2028.

Despite the improved results, the company increased its research and development (R&D) investment. Cumulative R&D expenses for the first three quarters totaled 23.533 billion won, up 32.5% from 17.761 billion won in the same period last year. OCT-598, a candidate drug for cancer resistant to existing treatments, entered Phase 1 clinical trials in December last year, and development of subsequent pipeline candidates is also underway.

This content was produced with the assistance of AI translation services.